Douglas Kling

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet · 2021 · 596 citations

Inflammation, Anti-inflammatory, Cardiovascular Disease +10

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

John J.P. Kastelein, Kevin C. Maki, Andrey V. Susekov et al. · Journal of clinical lipidology · 2013 · 226 citations · Full text

Metabolic Syndrome, Severe Hypertriglyceridemia, Health Policy +10

A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study

Michael Davidson, Judith Johnson, Michael W. Rooney et al. · Journal of clinical lipidology · 2012 · 185 citations

Nutrition, Omega-3 Fatty Acid, Lipid Nutrition +4

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein et al. · Nature Medicine · 2022 · 148 citations · Full text

Lipid Disorder, High-intensity Statins, Cardiovascular Disease +10

A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)

Kevin C. Maki, David G. Orloff, Stephen J. Nicholls et al. · Clinical Therapeutics · 2013 · 105 citations

Metabolic Syndrome, Cardiovascular Disease, Omega-3 Fatty Acid +9